Phase 3 Sickle Cell Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with sickle cell anemia (specifically the HbSS or HbS/B0-thalassemia types)
- Children between 6 months and 12 years old at the time of enrollment
- Children whose parent or guardian is willing and able to provide written consent on their behalf
- Children who weigh at least 7.5 kg (this restriction may be temporary — confirm with trial site)
Who may not be able to join:
- Children with an enlarged spleen that is affecting blood cell counts, specifically those with a platelet count below 150,000, hemoglobin below 5 g/dL, or a very low white blood cell count
- Children who have used the medication hydroxyurea within the past 6 months
- Children who have received a blood transfusion within the past 6 months (this restriction may be temporary — confirm with trial site)
- Children who are pregnant
- Children with already serious problems with their blood counts, based on specific combinations of low hemoglobin, low platelet count, or low reticulocyte (young red blood cell) count, as assessed by a doctor (this restriction may be temporary — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Patrick T McGann, MD, MS, Rhode Island Hospital and Hasbro Children's Hospital
Phone: 401-863-3000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of clinical, sickle cell adverse events (grade ≥ 3) as assessed by CTCAE v5.0; Number of non-SCA related adverse events (grade ≥3), including death as assessed by CTCAE v5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.